| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 11590,167
- Publication Date: February 28, 2023
- Appl. No: 16/465542
- Application Filed: December 01, 2017
- Assignees: Juno Therapeutic, Inc. (Seattle, WA, US), ACERTA PHARMA B.V. (AB Oss, NL)
- Claim: 1. A method of treatment of a cancer, the method comprising: (1) administering, to a subject having a cancer, T cells expressing a recombinant antigen receptor that specifically binds to an antigen associated with the cancer; and (2) administering to the subject a kinase inhibitor or a pharmaceutical composition comprising the inhibitor, wherein the inhibitor is the compound of Formula (II): [chemical expression included] or an enantiomer, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
- Claim: 2. The method of claim 1 , wherein: (i) the subject or the cancer (a) is resistant to ibrutinib or (b) comprises a population of cells that are resistant to ibrutinib; (ii) the subject or the cancer comprises a mutation or disruption in a nucleic acid encoding Bruton's tyrosine kinase (BTK), capable of reducing or preventing inhibition of the BTK by ibrutinib; or (iii) at the time of the administration in (1) and at the time of the administration in (2) the subject has relapsed following remission after treatment with, or been deemed refractory to treatment with ibrutinib.
- Claim: 3. The method of claim 2 , wherein the mutation in the nucleic acid encoding BTK comprises a C481S or C481R substitution, or a T474I or T474M substitution.
- Claim: 4. The method of claim 1 , wherein the cancer is selected from the group consisting of sarcomas, carcinomas, lymphomas, non-Hodgkin lymphomas (NHLs), diffuse large B cell lymphoma (DLBCL), leukemia, CLL, ALL, AML and myeloma.
- Claim: 5. The method of claim 1 , wherein the T cells recognize an antigen selected from ROR1, B cell maturation antigen (BCMA), tEGFR, Her2, L1-CAM, CD19, CD20, CD22, mesothelin, CEA, and hepatitis B surface antigen, anti-folate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, EGP-2, EGP-4, EPHa2, ErbB2, 3, or 4, erbB dimers, EGFR vIII, FBP, FCRL5, FCRH5, fetal acethycholine e receptor, GD2, GD3, HMW-MAA, IL-22R-alpha, IL-13R-alpha2, kdr, kappa light chain, Lewis Y, L1-cell adhesion molecule, (L1-CAM), Melanoma-associated antigen (MAGE)-A1, MAGE-A3, MAGE-A6, Preferentially expressed antigen of melanoma (PRAME), survivin, EGP2, EGP40, TAG72, B7-H6, IL-13 receptor a2 (IL-13Ra2), CA9, GD3, HMW-MAA, CD171, G250/CAIX, HLA-AI MAGE Al, HLA-A2 NY-ESO-1, PSCA, folate receptor-a, CD44v6, CD44v7/8, avb6 integrin, 8H9, NCAM, VEGF receptors, 5T4, Fetal AchR, NKG2D ligands, CD44v6, dual antigen, and an antigen associated with a universal tag, a cancer-testes antigen, mesothelin, MUC1, MUC16, PSCA, NKG2D Ligands, NY-ESO-1, MART-1, gp100, oncofetal antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), prostate specific antigen, PSMA, Her2/neu, estrogen receptor, progesterone receptor, ephrinB2, CD123, c-Met, GD-2, 0-acetylated GD2 (OGD2), CE7, Wilms Tumor 1 (WT-1), a cyclin, cyclin A2, CCL-1, CD138, and a pathogen-specific antigen.
- Claim: 6. The method of claim 1 , wherein the T cells comprise tumor infiltrating lymphocytes (TILs) or comprise genetically engineered T cells expressing a recombinant receptor that specifically binds to an antigen associated with the cancer.
- Claim: 7. The method of claim 6 , wherein the T cells are genetically engineered T cells expressing a recombinant receptor and the recombinant receptor is a transgenic T cell receptor (TCR) or a chimeric antigen receptor (CAR).
- Claim: 8. The method of claim 7 , wherein the recombinant receptor is a CAR and the CAR comprises an extracellular antigen-recognition domain that specifically binds to the antigen and an intracellular signaling domain comprising an ITAM.
- Claim: 9. The method of claim 8 , wherein the intracellular signaling domain comprises an intracellular domain of a CD3-zeta (CD3ζ) chain.
- Claim: 10. The method of claim 8 , wherein the chimeric antigen receptor (CAR) further comprises a costimulatory signaling region.
- Claim: 11. The method of claim 10 , wherein the costimulatory signaling region comprises a signaling domain of CD28 or 4-1BB.
- Claim: 12. The method of claim 1 , wherein the inhibitor irreversibly reduces or eliminates the activation of the target protein tyrosine kinase, specifically binds to a binding site in the active site of the target protein tyrosine kinase comprising an amino acid residue corresponding to residue C481 in the sequence set forth in SEQ ID NO:18, or reduces or eliminates autophosphorylation activity of the target protein tyrosine kinase.
- Claim: 13. The method of claim 1 , wherein the inhibitor is administered concurrently with or subsequently to initiation of administration of the T cells.
- Claim: 14. The method of claim 1 , wherein the inhibitor is administered subsequently to initiation of administration of the T cells.
- Claim: 15. The method of claim 14 , wherein the inhibitor is administered within, or within about 1 week of the initiation of the administration of the T cells.
- Claim: 16. The method of claim 1 , wherein the inhibitor is administered orally.
- Claim: 17. The method of claim 1 , wherein the inhibitor is administered at a total daily dosage amount of between 50 mg/day and 250 mg/day.
- Claim: 18. The method of claim 1 , wherein the inhibitor is administered in an amount that is about 200 mg/day.
- Claim: 19. The method of claim 1 , wherein the administered T cells comprise CD4+T cells, CD8+T cells, or CD4+T cells and CD8+T cells.
- Claim: 20. The method of claim 1 , wherein the administered T cells comprise administration of a dose comprising a number of cells between at or about 5×10 5 cells/kg body weight of the subject and at or about 1×10 7 cells/kg body weight of the subject.
- Claim: 21. The method of claim 1 , wherein the administered T cells comprise administration of a dose comprising a number of cells between at or about 1×10 7 and at or about 2×10 8 total T cells comprising the recombinant receptor.
- Claim: 22. The method of claim 1 , wherein the method further comprises administering a lymphodepleting chemotherapy prior to administration of the T cells.
- Claim: 23. The method of claim 1 , wherein the method further comprises administering an immune modulatory agent to the subject, wherein the administration of the cells and the administration of the immune modulatory agent are carried out simultaneously, separately or in a single composition, or sequentially, in either order.
- Claim: 24. The method of claim 1 , wherein the administered T cells exhibit increased or prolonged expansion or persistence in the subject as compared to a method in which the administered T cells are administered to the subject in the absence of the inhibitor.
- Claim: 25. The method of claim 1 , wherein the method reduces tumor burden to a greater degree or for a greater period of time as compared to the reduction that would be observed with a comparable method in which the administered T cells are administered to the subject in the absence of the inhibitor.
- Claim: 26. The method of claim 10 , wherein the costimulatory domain is a domain of 4-1BB.
- Claim: 27. The method of claim 1 , wherein the inhibitor is administered for a time period up to 1 year after initiation of the administration of the T cells.
- Claim: 28. The method of claim 27 , wherein the inhibitor is administered up to 3 months after initiation of the administration of the T cells.
- Claim: 29. The method of claim 1 , wherein the inhibitor is administered orally.
- Claim: 30. The method of claim 1 , wherein the inhibitor is administered twice a day.
- Claim: 31. The method of claim 27 , wherein the inhibitor is administered twice a day.
- Claim: 32. The method of claim 1 , wherein the administered T cells comprise cells that are autologous to the subject.
- Claim: 33. The method of claim 22 , wherein the lymphodepleting chemotherapy comprises administering fludarabine or cyclophosphamide to the subject.
- Claim: 34. The method of claim 5 , wherein the antigen is CD19.
- Claim: 35. The method of claim 1 , wherein the inhibitor is administered before initiation of administration of the T cells.
- Claim: 36. The method of claim 1 , wherein the inhibitor is administered twice a day for a cycle of 7, 14, 21, 28, 35 or 42 days.
- Claim: 37. The method of claim 1 , wherein the inhibitor is administered for 1 to 24 cycles.
- Patent References Cited: 4452773 June 1984 Molday ; 4690915 September 1987 Rosenberg ; 4795698 January 1989 Owen et al. ; 5200084 April 1993 Liberti et al. ; 5219740 June 1993 Miller et al. ; 6040177 March 2000 Riddell et al. ; 6207453 March 2001 Maass et al. ; 6410319 June 2002 Raubitschek et al. ; 6451995 September 2002 Cheung et al. ; 7070995 July 2006 Jensen ; 7265209 September 2007 Jensen ; 7354762 April 2008 Jensen ; 7446179 November 2008 Jensen et al. ; 7446190 November 2008 Sadelain et al. ; 7446191 November 2008 Jensen ; 7459554 December 2008 Dong et al. ; 8324353 December 2012 Jensen ; 8339645 December 2012 Nakawaki ; 8389282 March 2013 Sadelain et al. ; 8479118 July 2013 Lindersay ; 8802374 August 2014 Jensen ; 8822647 September 2014 Jensen ; 8911993 December 2014 June et al. ; 9278919 March 2016 Xu ; 9662343 May 2017 Tabuteau ; 10392446 August 2019 Stephan ; 20020131960 September 2002 Sadelain et al. ; 20030170238 September 2003 Gruenberg et al. ; 20110003380 January 2011 Miltenyi et al. ; 20130149337 June 2013 Cooper et al. ; 20130287748 October 2013 June et al. ; 20140134265 May 2014 Buggy et al. ; 20140271635 September 2014 Brogdon et al. ; 20140371241 December 2014 Buggy et al. ; 20150283178 October 2015 June et al. ; 20150299317 October 2015 Orentas et al. ; 20160362472 December 2016 Bitter et al. ; 20170210811 July 2017 Wong et al. ; 20180140602 May 2018 Angst et al. ; 20190161553 May 2019 Sather et al. ; 20190169572 June 2019 Shi et al. ; 20190233500 August 2019 Jantz et al. ; 20190292238 September 2019 Bitter et al. ; 20190298772 October 2019 Ports et al. ; 20190388471 December 2019 June et al. ; 20200016199 January 2020 Turtle et al. ; 20200031904 January 2020 Jantz et al. ; 20200277353 January 2020 Takahashi et al. ; 20200071670 March 2020 Shi et al. ; 20200172879 June 2020 Suri et al. ; 20200191774 June 2020 Christin et al. ; 20210121466 April 2021 Frankel et al. ; 20210147507 May 2021 Bayle et al. ; 20210161959 June 2021 Bot et al. ; 20210177896 June 2021 Porter et al. ; 20210213063 July 2021 Isaacs et al. ; 20210223248 July 2021 Turtle et al. ; 20220031746 February 2022 Gillenwater et al. ; 101084218 December 2007 ; 102209729 October 2011 ; 104844573 August 2015 ; 105153154 December 2015 ; 105392888 March 2016 ; 105399756 March 2016 ; 105732638 July 2016 ; 105884747 August 2016 ; 106163547 November 2016 ; 0 452 342 November 1994 ; 2 537 416 November 2014 ; 3747472 December 2020 ; 112298 February 2012 ; WO 1992/008796 May 1992 ; WO 1994/028143 December 1994 ; WO 1996/013593 May 1996 ; WO 1996/018105 June 1996 ; WO 1999/018129 April 1999 ; WO 1999/060120 November 1999 ; WO 2000/014257 March 2000 ; WO 2003/020763 March 2003 ; WO 2004/033685 April 2004 ; WO 2005/037836 April 2005 ; WO 2006/000830 January 2006 ; WO 2006/012422 February 2006 ; WO 2006/065946 June 2006 ; WO 2008/039218 April 2008 ; WO 2008/071937 June 2008 ; WO 2008/121742 October 2008 ; WO 2010/033140 March 2009 ; WO 2009/051822 April 2009 ; WO 2009/072003 June 2009 ; WO 2009/124119 October 2009 ; WO 2009/158571 December 2009 ; WO 2010/009342 January 2010 ; WO 2010/100070 September 2010 ; WO 2011/029046 March 2011 ; WO 2011/044186 April 2011 ; WO 2011/046964 April 2011 ; WO 2011/152351 December 2011 ; WO 2011/153514 December 2011 ; WO 2011/162515 December 2011 ; WO 2012/021444 February 2012 ; WO 2012/129514 September 2012 ; WO 2013/026837 February 2013 ; WO 2013/060098 May 2013 ; WO 2013/067274 May 2013 ; WO 2013/067277 May 2013 ; WO 2013/071154 May 2013 ; WO 2013/081016 June 2013 ; WO 2013/100631 July 2013 ; WO 2013/113097 August 2013 ; WO 2013/123061 August 2013 ; WO 2013/126726 August 2013 ; WO 2013/166321 November 2013 ; WO 2014/011984 January 2014 ; WO 2014/031687 February 2014 ; WO 2014/055668 April 2014 ; WO 2014/068527 May 2014 ; WO 2014/078578 May 2014 ; WO 2014/104757 July 2014 ; WO 2014/153270 September 2014 ; WO 2014/187262 November 2014 ; WO 2014/210085 December 2014 ; WO 2015/048689 April 2015 ; WO 2015/057992 April 2015 ; WO 2015/082499 June 2015 ; WO 2015/083008 June 2015 ; WO 2015/084892 June 2015 ; WO 2015083008 June 2015 ; WO 2015/127310 August 2015 ; WO 2015/142675 September 2015 ; WO 2015/146159 October 2015 ; WO 2015/157252 October 2015 ; WO 2015/157384 October 2015 ; WO 2015/165279 November 2015 ; WO 2015/169233 November 2015 ; WO 2015/192658 December 2015 ; WO 2016/014530 January 2016 ; WO 2016/020901 February 2016 ; WO 2016/024230 February 2016 ; WO 2016/112637 July 2016 ; WO 2016/164580 October 2016 ; WO 2017/214207 December 2017 ; WO 2018/085731 May 2018 ; WO 2019/109053 June 2019 ; WO 2019/213184 November 2019 ; WO 2020/113188 March 2020 ; WO 2010/052013 May 2020
- Other References: US 8,252,592 B2, 08/2012, Sadelain (withdrawn) cited by applicant ; Deniger et al. PLOS One, 2015, DOI: 10.137. cited by examiner ; Abramson et al., “High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration,” J Clin Oncol (2018) 36(5_suppl):120. cited by applicant ; Abramson et al., “TRANSCEND NHL 001: Immunotherapy with the CD19-directed CAR T-cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,” Blood (2016) 128:4192 Abstract. cited by applicant ; Advani et al., “Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies,” J Clin Oncol. (2013)31:88-94. cited by applicant ; Sidaway et al., “Ibrutinib supercharges CAR T cells,” Nature Reviews Clin Oncol (2016) 13(4):204. doi:10.1038/nrclinonc.2016.28. cited by applicant ; Barf et al., “Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile,” J Pharmacol Exp Ther (2017) 363(2):240-252. cited by applicant ; Bridgeman et al., “The optimal antigen response of chimeric antigen receptors harboring the CD3 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex,” J Immunol (2010) 184:6938-6949. cited by applicant ; Buggy et al., “Bruton tyrosine kinase (BTK) and its role in B-cell malignancy,” Int Rev Immunol. (2012) 31:119-132. cited by applicant ; Chiron et al., “Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell Tymphoma,” Cancer Discov (2014) 4(9):1022-1035. cited by applicant ; Gardner et al., “Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults,” Blood (2017) 129(25):3322-3331. cited by applicant ; Gauthier et al., “Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and/or refractory CLL,” Blood. 2018;132:299. cited by applicant ; Herman et al., “The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic Teukemia,” Clin Cancer Res. (2017)23: 2831-2841. cited by applicant ; Jackson et al., “Driving CAR T-cells forward,” Nat Rev Clin Oncol (2016) 13(6):370-383. cited by applicant ; Kahl et al., “Advances and issues in mantle cell lymphoma research: report of the 2014 mantle cell lymphoma consortium workshop,” Leukemia & Lymphoma (2015) 56(9):2505. cited by applicant ; Kandalaft et al., “A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer,” J Transl Med (2012) 10:157. cited by applicant ; Kedmi et al., “Ibrutinib, bendamustine, rituximab combination for relapsed and refractory aggressive B cell lymphoma—Interim analysis of phase II clinical trial,” Blood. Nov. 21, 2018; 132:4186. cited by applicant ; Kokhaei et al., Ibrutinib—A double-edge sword in cancer and autoimmune disorders. J Drug Target. 2016;24:373-385. cited by applicant ; Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome,” Blood. (2014) 124(2):188-95. cited by applicant ; Nastoupil et al., “Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular and marginal zone lymphoma: An open label, phase II study,” Blood. Nov. 21, 2018; 132:447. cited by applicant ; Patel et al., “Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells,” Clin Cancer Res (2017) 23(14):3734-3743. cited by applicant ; Podhorecka et al., “Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number,” Oncotarget (2017) 8(21):34661-34669. cited by applicant ; Porter et al., “Chimeric antigen receptor-modified T cells in chronic lymphoid Teukemia,” N Engl J Med. Aug. 25, 2011;365(8):725-33. cited by applicant ; Qin et al., “Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib,” J Immunother (2020) 43(4):107-120. cited by applicant ; Ritchie et al., “Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia,” Mol Ther (2013) 21(11):2122-2129. cited by applicant ; Sahaf B, Tebaykin D, Hopper M, Cheung P, Bittencourt F, Cutler CS, et al. Ibrutinib-Mediated Inhibition of cGVHD Pathogenic Pre-Germinal Center B Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T Cells. ASBMT 2018. cited by applicant ; Sommermeyer et al., “Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo,” Leukemia (2016) 30(2):492-500. cited by applicant ; Turtle et al., “Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition,” Blood. (2014) 124 (21): 384. cited by applicant ; Wang et al., “Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a singlearm, multicentre, phase 2 trial,” Lancet. (2018) 391:659-667. cited by applicant ; Wang et al., “Bruton's tyrosine kinase and its isoforms in cancer,” Front Cell Dev Biol (2021) 9:668996. cited by applicant ; Wilson et al., “Targeting B cell receptor signaling with ibrutinib in diffuse large B cell Tymphoma,” Nat Med. (2015) 21:922-926. cited by applicant ; Younes et al., “A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL)” Blood. Nov. 21, 2018; 132:784. cited by applicant ; Afar et al., “Regulation of Btk by Src family tyrosine kinases,” Mol Cell Biol (1996) 16(7):3465-3471. cited by applicant ; AG1478 (Tyrphostin) Kinase Profiling Inhibitor Database, retrieved from the internet URL: http://www.kinase-screen.mrc.ac.uk/screening-compounds/348815; retrieved Feb. 21, 2020. cited by applicant ; Ahmed et al., “Human Epidermal Growth Factor Receptor 2 (HER2)—Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.” J Clin Oncol. May 20, 2015; 33(15): 1688-1696. cited by applicant ; Akinleye et al., “Ibrutinib and novel BTK inhibitors in clinical development,” J Hematol Oncol (2013) 6:59. cited by applicant ; Alonso-Camino et al., “CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors,” Mol Ther Nucleic Acids (2013) 2(5):e93. cited by applicant ; Anastassiadis et al., “Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity,” Nat Biotechnol (2011) 29(11):1039-1045. cited by applicant ; Apsel et al., “Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases,” Nat Chem Biol. (2008) 4(11):691-699. cited by applicant ; Bair et al., “Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia,” Am J Hematol. (2019) 94(S1):S10-S17. cited by applicant ; Bamborough et al., “Assessment of chemical coverage of kinome space and its implications for kinase drug discovery,” J Med Chem (2008) 51(24)7898-7914. cited by applicant ; Bamborough et al., “N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics,” Bioorg Med Chem Lett. (2007) 17(15):4363-4368. cited by applicant ; Barf et al., “Irreversible protein kinase inhibitors: balancing the benefits and risks,” J Med Chern (2012) 55(14):6243-6262. cited by applicant ; Barrett et al., “Chimeric Antigen Receptor Therapy for Cancer,” Annual Review of Medicine (2013) 65:333-347. cited by applicant ; Berg et al., “Tec family kinases in T lymphocyte development and function,” Annu Rev Immunol (2005) 23:549-600. cited by applicant ; Berglof et al., “Targets for Ibrutinib Beyond B Cell Malignancies,” Scandinavian Journal of Immunology (2015) 82:208-217. cited by applicant ; Boris-Lawrie et al., “Recent advances in retrovirus vector technology,” Current Opinion in Genetics & Development (1993) 3(1):102-109. cited by applicant ; Brash et al., “Strontium phosphate transfection of human cells in primary culture: stable expression of the simian virus 40 large-T-antigen gene in primary human bronchial epithelial cells,” Mol. Cell Biol. (1987) 7: 2031-2034. cited by applicant ; Brentjens et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” Sci Transl Med. (2013) 5(177):177ra38. cited by applicant ; Brentjens et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood (2011) 118(18):4817-4828. cited by applicant ; Britschgi et al., “HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation,” British Journal of Haematology (2008) 141(2):179-187. cited by applicant ; BTK Target Report Card CHEMBL5251, retrieved from the internet URL: https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL5251/retrieved Feb. 21, 2020. cited by applicant ; Burns et al., “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,” Proc. Natl. Acad. Sci. USA (1993) 90:8033-8037. cited by applicant ; Busch et al., “Role of memory T cell subsets for adoptive immunotherapy,” Semin Immunol (2016) 28(1):28-34. cited by applicant ; Byrd et al., “Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia” N Engl J Med. Jan. 28, 2016; 374(4): 323-332. cited by applicant ; Byrd et al., “Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib,” Blood (2015) 125(16):2497-2506. cited by applicant ; Byrd, “Dr. John Byrd Discusses ACP 196 or Acalabrutinib, a new BTK inhibitor,” ASH 2015. cited by applicant ; Carlens et al., “Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution,” Exp Hematol (2000) 28(10): 1137-46. cited by applicant ; Carrillo et al., “The Multiple Sequence Alignment Problem in Biology,” SIAM J Appl Math (1988) 48(5):1073-1082. cited by applicant ; Cavalieri et al., “Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence,” Blood (2003) 102(2): 497-505. cited by applicant ; Cheadle et al., “Chimeric antigen receptors for T-cell based therapy,” Methods Mol Biol. (2012);907:645-66. cited by applicant ; Cheng et al., “Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction,” Biochem Pharmacol. (1973) 22: 3099-3108. cited by applicant ; Chervin et al., “Engineering higher affinity T cell receptors using a T cell display system,” J Immunol Methods (2008) 339(2):175-184. cited by applicant ; Chicaybam et al., “An efficient low cost method for gene transfer to T lymphocytes,” PLoS ONE (2013) 8(3): e60298. cited by applicant ; Cho et al., “Human mammalian cell sorting using a highly integrated micro-fabricated fluorescence-activated cell sorter (microFACS),” Lab Chip (2010) 10: 1567-1573. cited by applicant ; Chothia et al., “The outline structure of the T-cell alpha beta receptor,” EMBO J (1988) 7(12):3745-3755. cited by applicant ; Clinical Trial Study Record No. NCT01865617. First posted May 31, 2013. Updated Oct. 26, 2017. Accessed Jun. 5, 2018. cited by applicant ; Clinical Trial Study Record No. NCT02631044. First posted Dec. 15, 2015. Updated Aug. 26, 2019. Accessed Sep. 23, 2019. cited by applicant ; Clinicaltrials.gov Identifier NCT01822652. First posted Apr. 2, 2013. Last updated May 3, 2019. cited by applicant ; Clinicaltrials.gov Identifier NCT02029443. First posted Jan. 9, 2014. Last updated Feb. 1, 2019. cited by applicant ; Clinicaltrials.gov identifier NCT02213926. First posted on Aug. 12, 2014. Last update posted Jul. 10, 2019. cited by applicant ; Clinicaltrials.gov Identifier NCT02315612. First posted Dec. 12, 2014. Last updated Oct. 9, 2019. cited by applicant ; Clinicaltrials.gov identifier NCT02717624. First posted on Mar. 24, 2016. Last update posted Mar. 28, 2019. cited by applicant ; Clinicaltrials.gov identifier NCT02735876. First posted on Apr. 13, 2016. Last update posted May 13, 2016. cited by applicant ; Clinicaltrials.gov Identifier NCT03331198. First posted Nov. 6, 2017. Last updated Sep. 18, 2019. cited by applicant ; Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect,” Blood (2003) 101:1637-1644. cited by applicant ; Corvus Pharmaceuticals, “Our Pipeline | CPI-444 | CPI-006 | CPI-818 |,” (2019) https://www.corvuspharma.com/our-science/our-pipeline/. cited by applicant ; Covey et al., “ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL).” Cancer Res 2015;75(15 Suppl):Abstract No. 2596. cited by applicant ; D'Arena et al., “Regulatory T-cell No. is increased in chronic lymphocytic leukemia patients and correlates with progressive disease,” Leuk Res (2011) 35(3):363-368. cited by applicant ; Davids et al., “Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase,” Future Oncology (2014) 10(6):957-967. cited by applicant ; Davila et al., “CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia,” PLOS One (2013) 8(4):e61338. cited by applicant ; Davila et al., “How do CARs work?: Early insights from recent clinical studies targeting CD19,” Oncoimmunology (2012) 1(9):1577-1583. cited by applicant ; Davis et al., “Comprehensive analysis of kinase inhibitor selectivity,” Nat Biotechnol (2011) 29(11):1046-1051. cited by applicant ; Di Paolo et al., “Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis,” Nat Chem Biol (2011) 7(1):41-50. cited by applicant ; Dimauro et al., “Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity,” J Med Chem. (2006) 49(19): 5671-86. cited by applicant ; Dubovsky et al., “Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.” Blood. Oct. 10, 2013;122(15):2539-49. cited by applicant ; Dudley et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science (2002) 298(5594):850-854. cited by applicant ; Emanuel et al., “Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors,” Mol Pharmacol. Feb. 2008;73(2):338-48. cited by applicant ; Evans et al., “Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,” ASH Annual Meeting. Dec. 10-13, 2011. Poster. cited by applicant ; Evans et al., “Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans,” JPET #203489. Retrieved on Sep. 27, 2019. Retrieved on http://jpet.aspetjournals.org/content/jpet/suppl/2013/05/24/jpet.113.203489.DC1/jpet203489SupplMethTabsREV.pdf. cited by applicant ; Fabian et al., “A small molecule-kinase interaction map for clinical kinase inhibitors,” Nat Biotechnol. (2005) 23(3): 329-36. cited by applicant ; Fedorov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses,” Science Translational Medicine (2013) 5(215):215ra172. cited by applicant ; Fidanze et al., “Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases,” Bioorg Med Chem Lett. (2010) 20(8): 2452-2455. cited by applicant ; Fraietta et al., “Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.” Blood. Mar. 3, 2016;127(9):1117-27. cited by applicant ; Gabrilovich et al., “Myeloid-derived suppressor cells as regulators of the immune system,” Nat Rev Immunol (2009) 9(3):162-174. cited by applicant ; Geyer et al., “Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell administration in Adults with Relapsed/Refractory CLL.” Blood 2016 128:58. cited by applicant ; Gill et al., “CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.” J. Clin. Oncol. May 2017;35(15 Supp.):7509. cited by applicant ; Godin et al., “Microfluidics and photonics for Bio-System-on-a-Chip: a review of advancements in technology towards a microfluidic flow cytometry chip,” J Biophotonics (2008) 1(5):355-376. cited by applicant ; Goldberg et al., “Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase,” J Med Chem. Apr. 10, 2003;46(8):1337-49. cited by applicant ; Gunderson et al., “Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer,” Cancer Discov (2016) 6(3):270-285. cited by applicant ; Hall et al., “Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells,” J Med Chem (2009) 52(10):3191-3204. cited by applicant ; Han et al., “Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges,” J Hematology & Oncology (2013) 6:47. cited by applicant ; Heim et al., “Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells,” Mol Cancer (2007) 6:57. cited by applicant ; Hendriks et al., “Targeting Bruton's tyrosine kinase in B cell malignancies,” Nat Rev Cancer (2014) 14(4):219-232. cited by applicant ; Hermans et al., “The VITAL assay: a versatile fluoro metric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo,” J Immunol Methods (2004) 285(1):25-40. cited by applicant ; Holler et al., “In vitro evolution of a T cell receptor with high affinity for peptide/MHC,” PNAS (2000) 97(10):5387-5392. cited by applicant ; Holler et al., “TCRs with high affinity for foreign pMHC show self-reactivity,” Nat Immunol (2003) 4(1):55-62. cited by applicant ; Holliger et al., “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody,” Protein Engineering Design and Selection (1996) 9(3):299-305. cited by applicant ; Honda et al., “The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils,” Nat Immunol (2012) 13(4):369-378. cited by applicant ; Honigberg et al., “The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy,” Proc Natl Acad Sci USA (2010) 107(29):13075-13080. cited by applicant ; Huang et al., “Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant,” J Med Chem. Jun. 24, 2010;53(12):4701-4719. cited by applicant ; Huang et al., “DNA transposons for modification of human primary T lymphocytes,” Methods Mol Biol (2009) 506:115-126. cited by applicant ; Hudecek et al., “Receptor affinity and extracellular domain modifications affect tumor Yecognition by ROR1-specific chimeric antigen receptor T cells,” Clin Cancer Res (2013) 19(12):3153-3164. cited by applicant ; Hur et al., “Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase,” Bioorg Med Chem Lett. Nov. 15, 2008;18(22):5916-5919. cited by applicant ; Ibrutinib (RX) dosing and uses. Retrieved on Sep. 27, 2019. Retrieved on https://reference.medscape.com/drug/imbruvica-ibrutinib-999896. cited by applicant ; IKK-2 Inhibitor IV (TPCA-1) Kinase Profiling Inhibitor Database, retrieved from the internet URL: http://www.kinase-screen.mrc.ac.uk/screening-compounds/345889; retrieved Feb. 21, 2020. cited by applicant ; Imbruvica capsules and tablets, Highlights of Prescribing Information. Initial US Approval 2013. Revised Jul. 2019. cited by applicant ; Imbruvica capsules, Highlights of Prescribing Information. Initial US Approval 2013. Revised Jan. 2015. cited by applicant ; Jain et al., “Initial treatment of CLL: integrating biology and functional status,” Blood (2015) 126(4):463-470. cited by applicant ; Janeway et al., Immunobiology: The Immune System in Health and Disease, 3rd ED., Current Biology Publications (1997), p. 4:33. cited by applicant ; Jensen et al., “Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans,” Biol Blood Marrow Transplant (2010) 16(9):1245-1256. cited by applicant ; Jiang et al., “LZTFL1 Upregulated by All-Trans Retinoic Acid during CD4+T Cell Activation Enhances IL-5 Production,” J Immunol (2016) 196(3):1081-1090. cited by applicant ; Johnson et al., “Kinomics: methods for deciphering the kinome,” Nat Methods (2005) 2(1):17-25. cited by applicant ; Johnston, “Biolistic transformation: microbes to mice,” Nature (1990) 346:776-777. cited by applicant ; Jores et al., “Resolution of hypervariable regions in T-cell receptor beta chains by a modified Wu-Kabat index of amino acid diversity.,” PNAS (1990) 87(23):9138-9142. cited by applicant ; Juno Corporate Presentation. Retrieved on http://ir.junotherapeutics.com. Retrieved on Jan. 2018. cited by applicant ; Juno Corporate Presentation. Retrieved on http://ir.junotherapeutics.com. Retrieved on Sep. 2017. cited by applicant ; Juno Therapeutics, “Juno's Investigational CAR T Cell Product Candidates JCAR014 and JCAR018 Demonstrate Encouraging Clinical Responses in Patients with B-Cell Cancers,” Published on Dec. 6, 2015. Retrieved on http://ir.junotherapeutics.com/news-releases/news-release-details/junos-investigational-car-t-cell-product-candidates-jcar014-and Retrieved on Mar. 6, 2018. cited by applicant ; Kalos et al., “T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia,” Sci Transl Med (2011) 3(95):95ra73. cited by applicant ; Karaman et al., “A quantitative analysis of kinase inhibitor selectivity,” Nat Biotechnol. Jan. 2008;26(1):127-32. cited by applicant ; Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J Mol Biol (1999) 293(1):41-56. cited by applicant ; Klebanoff et al., “Sorting through subsets: Which T cell populations mediate highly effective adoptive immunotherapy?” J Immunother (2012) 35(9):651-660. cited by applicant ; Kochenderfer et al., “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells,” Blood (2012) 119:2709-2720. cited by applicant ; Kochenderfer et al., “Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor,” J Clin Oncol (2015) 33(6):540-549. cited by applicant ; Kochenderfer et al., “Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor,” J. Immunotherapy (2009) 32(7): 689-702. cited by applicant ; Kochenderfer et al., “Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors,” Nat Rev Clin Oncol (2013) 10(5):267-276. cited by applicant ; Koste et al., “T-cell receptor transfer into human T cells with ecotropic retroviral vectors,” Gene Therapy (2014) 21:533-538. cited by applicant ; Kotb et al., “Bacterial pyrogenic exotoxins as superantigens,” Clinical Microbiology Reviews (1995) 8:411-426. cited by applicant ; Kurucz et al., “A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor,” PNAS (1993) 90(9):3830-3834. cited by applicant ; Lamers et al., “Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells,” Blood (2011) 117(1):72-82. cited by applicant ; Lannutti et al., “ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer,” AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 408. and retraction, published in Cancer Res 2017; 77(17). cited by applicant ; Lee et al., “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic Teukaemia in children and yound adults: a phase 1 dose escalation trial,” The Lancet (2015) 385(9967): 517-528. cited by applicant ; Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol (2003) 27(1):55-77. cited by applicant ; Legouill, S., “ACP-196 (Acalabrutinib) in MCL”; presented in Bologna, 2016, available at http://www.ercongressi.it/slides-NDH-Carlton/10-05/Le-Gouill.pdf. cited by applicant ; LFM-A13 Product Page, Adooq Bioscience, retrieved from the internet URL: https://www.adooq.com/lfm-a13.html, retrieved Feb. 21, 2020. cited by applicant ; Li et al., “Directed evolution of human T-cell receptors with picomolar affinities by phage display,” Nat Biotechnol (2005) 23(3):349-354. cited by applicant ; Li et al., “Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity,” J. Med. Chem. (2014) 57(12):5112-5128. cited by applicant ; Locke et al., “Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: a Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL),” Blood (2015) 126:3991. cited by applicant ; Logan et al., “Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic Teukemia,” Leukemia (2013) 27(8): 1659-1665. cited by applicant ; Long et al., “Ibrutinib treatment improves T cell number and function in CLL patients,” J Clin Invest. Aug. 1, 2017;127(8):3052-3064. cited by applicant ; Long et al., “Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients,” Blood (2015) 126:2940. cited by applicant ; Long et al., “Ilbrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism.” Blood 2016 128:3238. cited by applicant ; Lou et al., “Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies,” J Med Chem (2012) 55(10):4539-4550. cited by applicant ; Lupton et al., “Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene,” Mol and Cell Biol (1991) 11(6):3374-3378. cited by applicant ; Ma et al., “The challenge of selecting protein kinase assays for lead discovery optimization,” Expert Opin Drug Discov (2008) 3(6):607-621. cited by applicant ; Maddocks et al., “Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.” JAMA Oncol. Apr. 2015;1(1):80-7. cited by applicant ; Mahajan et al., “Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].” J Biol Chem (1999) 274(14):9587-9599. cited by applicant ; Mamonkin et al., “A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.” Blood. Aug. 20, 2015;126(8):983-92. cited by applicant ; Manuri et al., “piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies,” Hum Gene Ther (2010) 21(4):427-437. cited by applicant ; Maude et al., “Chimeric antigen receptor T cells for sustained remissions in leukemia,” N Engl J Med. Oct. 16, 2014;371(16):1507-17. cited by applicant ; Methods in Molecular Medicine, vol. 58: Metastasis Research Protocols, vol. 2: Cell Behavior In Vitro and In Vivo, p. 17-25 Edited by: S. A. Brooks and U. Schumacher © Humana Press Inc., Totowa, NJ. cited by applicant ; Miller et al., “Improved retroviral vectors for gene transfer and expression,” Biotechniques (1989) 7(9):980-982. cited by applicant ; Miller, “Retrovirus packaging cells,” Hum Gene Ther (1990) 1(1):5-14. cited by applicant ; Mirams et al., “Prediction of Thorough QT study results using action potential simulations based on ion channel screens,” J Pharmacol Toxicol Methods. (2014) 70(3):246-54. cited by applicant ; Moreira et al., “Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls,” Leukemia (2013) 27(1):136-141. cited by applicant ; Mullen et al., “Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system,” Proc Natl Acad Sci U.S.A (1992) 89:33-37. cited by applicant ; Muranski et al., “Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?” Nat Clin Pract Oncol (2006) 3(12):668-681. cited by applicant ; Nagorsen et al., “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res (2011) 317(9):1255-1260. cited by applicant ; Nijhof et al., “Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab,” Leukemia (2015) 29(10):2039-2049. cited by applicant ; Palmer et al., “Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia,” Br J Haematol (2008) 141(5):607-614. cited by applicant ; Park et al., “Adoptive transfer of chimeric antigen receptor re-directed cytolytic T Tymphocyte clones in patients with neuroblastoma,” Mol Ther (2007) 15(4):825-833. cited by applicant ; Park et al., “CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.” Blood. Jun. 30, 2016; 127(26): 3312-3320. cited by applicant ; Park et al., “HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis,” Arthritis Res Ther (2016) 18:91. cited by applicant ; Park et al., “Treating cancer with genetically engineered T cells,” Trends Biotechnol (2011) 29(11):550-557. cited by applicant ; PCI 29732 Product Page, Adooq Bioscience, retrieved from the internet URL: https://www.adooq.com/pci-29732.html retrieved Feb. 21, 2020. cited by applicant ; Porter et al., “Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia,” Sci Transl Med (2015) 7(303):303ra139. cited by applicant ; Porter et al., “Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL.” Blood 2014 124:1982. cited by applicant ; Pott et al., “MRD detection in B-cell non-hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCT,” Methods Mol Biol (2013) 971:175-200. cited by applicant ; Qin et al., “Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib and Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia,” Blood 2016, 128:3231. cited by applicant ; Qin et al., “Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib and Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia,” poster, presented at American Society of Hematology (ASH) 2016 Annual Meeting, Dec. 3-6, 2016, San Diego, CA. Poster 3231. cited by applicant ; Qiu et al., “Current understanding of tyrosine kinase BMX in inflammation and its inhibitors,” Burns & Trauma (2014) 2(3): 121-124. cited by applicant ; QL47 Product Page, Adooq Bioscience, retrieved from the internet URL: https://www.adooq.com/ql47.html, retrieved Feb. 21, 2020. cited by applicant ; Ramsay et al., “Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.” J Clin Invest. Jul. 2008;118(7):2427-37. cited by applicant ; Remsing et al., “Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells,” Leukemia. Mar. 2009;23(3):477-485. cited by applicant ; Riddell et al., “Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant,” Human Gene Therapy (1992) 3:319-338. cited by applicant ; Rosen et al., “Identification of Small Molecule Modulators to Enhance the Therapeutic Properties of Chimeric Antigen Receptor T Cells,” Blood (2016) 128(22):4712. cited by applicant ; Rosenberg et al., “Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy,” Clin Cancer Res (2011) 17(13):4550-4557. cited by applicant ; Rosenberg, “Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know,” Nat Rev Clin Oncol (2011) 8(10):577-585. cited by applicant ; Ruella et al., “Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms” Blood 2016 128:2159. cited by applicant ; Ruella et al., “Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.” Leukemia. Jan. 2017;31(1):246-248. cited by applicant ; Ruella et al., “The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.” Clin Cancer Res. Jun. 1, 2016;22(11):2684-96. cited by applicant ; Sadelain et al., “The basic principles of chimeric antigen receptor (CAR) design,” Cancer Discov (2013) 3(4):388-398. cited by applicant ; Sagiv-Barfi et al., “Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK,” Proc Natl Acad Sci USA (2015) 112(9):E966-972. cited by applicant ; Savoldo et al., “CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients,” J Clin Invest (2011) 121(5):1822-1826. cited by applicant ; Scarpa et al., “Characterization of recombinant helper retroviruses from Moloney-based vectors in ecotropic and amphotropic packaging cell lines,” Virology (1991) 180(2):849-852. cited by applicant ; Schlueter et al., “Specificity and Binding Properties of a Single-chain T Cell Receptor,” J Mol Biol (1996) 256(5):859-869. cited by applicant ; Schuler et al., “SYFPEITHI: database for searching and T-cell epitope prediction,” Methods Mol Biol. (2007) 409: 75-93. cited by applicant ; Schwartzberg et al., “TEC-family kinases: regulators of T-helper-cell differentiation,” Nature Reviews Immunology (2005) 5:284-295. cited by applicant ; Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev (2010) 36:458-467. cited by applicant ; Sharma et al., “Efficient Sleeping Beauty DNA Transposition From DNA Minicircles,” Molec Ther Nucl Acids (2013) 2:e74. cited by applicant ; Shimomura et al., “MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel,” Mol Cancer Ther. Jan. 2010;9(1):157-166. cited by applicant ; Sidaway et al., “Haematological cancer: Ibrutinib supercharges CAR T cells.” Nat Rev Clin Oncol. Apr. 2016;13(4):204. cited by applicant ; Singh et al., “ProPred: prediction of HLA-DR binding sites,” Bioinformatics (2001) 17(12):1236-1237. cited by applicant ; Soo Hoo et al., “Characterization of a single-chain T-cell receptor expressed in Escherichia coli,” PNAS (1992) 89(10):4759-4763. cited by applicant ; Stiff et al., “Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.” Cancer Res. Apr. 15, 2016;76(8):2125-36. cited by applicant ; Terakura et al., “Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells,” Blood (2012) 119(1):72-82. cited by applicant ; Themeli et al., “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy,” Nat Biotechnol (2013) 31(10):928-933. cited by applicant ; Tsou et al., “6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity,” J Med Chem. (2001) 44(17): 2719-34. cited by applicant ; Tsou et al., “Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity,” J Med Chem. (2005) 48(4): 1107-31. cited by applicant ; Tsukahara et al., “CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models,” Biochem Biophys Res Commun (2013) 438(1):84-89. cited by applicant ; Turtle et al., “Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lyphoma and Chronic Lyphocytic Leukemia: Fludarabine and Cyclophosphamide Lyphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes,” Blood (2015) 126:184. cited by applicant ; Turtle et al., “CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia,” Blood (2016) 128(22): 56. cited by applicant ; Turtle et al., “CD19 Car-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.” J Clin Invest. Jun. 1, 2016;126(6):2123-38. cited by applicant ; Turtle et al., “Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.” J Clin Oncol. Sep. 10, 2017;35(26):3010-3020. cited by applicant ; Turtle et al., “Engineered T cells for anti-cancer therapy,” Engineered T cells for anti-cancer therapy, Curr Opin Immunol (2012) 24(5):633-639. cited by applicant ; Turtle et al., “Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells,” Sci Transl Med (2016) 8(355):355ra116. cited by applicant ; Turtle et al., “Rate of durable complete response in All, Nhl, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells,” 2016 ASCO meeting abstract 102, J. Clin. Oncol. (2016) 34(15):Suppl. Abstr 102. cited by applicant ; Van Tendeloo et al., “High-level transgene expression in primary human T Tymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery,” Gene Therpay (2000) 7(16):1431-1437. cited by applicant ; Verhoeyen et al., “Lentiviral vector gene transfer into human T cells,” Methods Mol Biol (2009) 506:97-114. cited by applicant ; Wang et al., “Discovery of Disubstituted lmidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors,” ACS Med Chem Lett (2012) 3(9):705-709. cited by applicant ; Wang et al., “Phenotypic and Functional Attributes of Lentivirus Modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale,” J Immunother (2012) 35(9):689-701. cited by applicant ; Wigler et al., “Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells,” Cell (1997) 2:223. cited by applicant ; Wilson, W.H., “Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.” N Engl J Med. Jan. 28, 2016;374(4):386-8. cited by applicant ; Wong et al., “Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families,” Clin Cancer Res. Jun. 15, 2011;17(12):4031-4041. cited by applicant ; Woyach et al., “Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib,” N Engl J Med (2014) 370(24):2286-2294. cited by applicant ; Woyach et al., “Targeted therapies in CLL: mechanisms of resistance and strategies for management.” Blood. Jul. 23, 2015;126(4):471-7. cited by applicant ; Wu et al., “Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor,” Journal of Hematology & Oncology (2016) 9:Article No. 21. cited by applicant ; Wu et al., “Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook,” Cancer J (2012) 18(2):160-175. cited by applicant ; Wu et al., “Second-generation inhibitors of Bruton tyrosine kinase,” J Hematol Oncol (2016) 9:80. cited by applicant ; Wu et al., “The transcription factor musculin promotes the unidirectional development of peripheral Treg cells by suppressing the TH2 transcriptional program,” Nat Immunol (2017) 18(3):344-353. cited by applicant ; Wulfing et al., “Correctly folded T-cell receptor fragments in the periplasm of Escherichia coli. Influence of folding catalysts,” J Mol Biol (1994) 242(5):655-669. cited by applicant ; Xu et al., “RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents,” J Pharmacol Exp Ther (2012) 341(1):90-103. cited by applicant ; Younes, A. “Promising Novel Agents for Aggressive B-Cell Lymphoma.” Hematol Oncol Clin North Am. Dec. 2016;30(6):1229-1237. cited by applicant ; Young et al., “Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834,” Bioorg Med Chem Lett (2015) 25(6):1333-1337. cited by applicant ; Zhao et al., “Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of Car T Cells,” Cancer Cell (2015) 28(4):415-428. cited by applicant ; Zhong et al., “Targeting interleukin-2-inducible T-cell kinase (ITK) and resting Tymphocyte kinase (RLK) using a novel covalent inhibitor PRN694,” J Biol Chem (2015) 290(10):5960-5978. cited by applicant ; Zhou et al., “Novel mutant-selective EGFR kinase inhibitors against EGFR T790M,” Nature (2009) 432(7276):1070-1074. cited by applicant ; Zirn et al., “All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo,” Oncogene (2005) 24(33):5246-5251. cited by applicant ; Butler et al., “Human cell-based artificial antigen-presenting cells for cancer immunotherapy,” Immunol Rev. (2014) 257(1):191-209. cited by applicant ; Clinical Trial Study Record No. NCT02435849, “Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,” (Eliana), May 6, 2015. cited by applicant ; Clinical Trial Study Record No. NCT02445248, “Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients,” (Juliet), May 15, 2015. cited by applicant ; Meisenberg et al., “Reduced charges and costs associated with outpatient autologous stem cell transplantation,” Bone Marrow Transplant. (1998) 21(9):927-32. cited by applicant ; Myers et al., “Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia,” J Immunother Cancer. (2021) 9(4):e002056. cited by applicant ; Park et al. “Phase I trial of autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL,” Blood (Nov. 2013) 122(21):874. cited by applicant ; Slovin et al., “Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) DOD,” Grant Log# PC081632, https://cdmrp.army.mil/pubs/video/pc/pdf/slovin_poster.pdf, 2013, poster presentation. cited by applicant ; Stiff et al., “Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis,” Bone Marrow Transplant. (2006) 38(11):757-64. cited by applicant
- Primary Examiner: Shiao, Rei Tsang
- Attorney, Agent or Firm: Morrison Foerster LLP
|
